Dextrin hydrogel for biomedical applications
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 8, 2015
Grant Date -
Feb 21, 2013
app pub date -
Dec 9, 2010
filing date -
Dec 10, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A hydrogel formulation of oxidized dextrin is reticulated with adipic acid dihydrazide, which may embody polysaccharides, proteins, nanogels, granular materials, bioactive molecules and cells for tissue regeneration and controlled drug delivery. A hydrogel can be injectable, highly biocompatible and biodegradable, for tissue regenerative applications, performing simultaneously as a vehicle e.g. for nanogels, granular materials and cells, and as controlled drug delivery systems, e.g. of hydrophobic molecules and therapeutic proteins.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully